Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3233 in BRAF mutation advanced malignant melanoma
NCT03453034Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQ-B3233 in Malignant Melanoma (MM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicity at 28 days and 4 more. Status: unknown.
02
Drugs
TQ-B3233
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03453034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453034.